N-Glycans on biotherapeutics can affect immunogenicity, pharmacokinetics and pharmacodynamics, making characterization of N-glycans essential in the development process. Here we present rapid N-glycan ...
Glycans on therapeutic proteins, such as antibodies, must be monitored. [Waters] During the manufacturing of a biotherapeutic, a processor must track many features, including glycans. These molecules ...
Monoclonal antibodies (mAbs) dominate the biotherapeutic market, with numerous products designed to provide treatments for cancer or immune diseases such as Crohn’s disease, rheumatoid arthritis, and ...
The structure of N-linked glycans can play a critical role in the pharmacology of therapeutic proteins, potentially affecting immunogenicity, pharmacokinetics and pharmacodynamics. This makes the ...
HAYWARD, Calif., June 6, 2017 /PRNewswire-iReach/ -- ProZyme, Inc., a leading manufacturer of reagents and tools for glycobiology, today announced the launch of the Gly-X™ N-Glycan Rapid Release and ...
ProZyme, Inc., manufacturer of bioreagents for glycobiology, and BiOptic Inc. of Taiwan, manufacturer of instruments for DNA analysis by capillary gel electrophoresis (CGE), announced an agreement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback